Karl Lintel is the founder of BioShin. BioShin has raised $60M in total funding. Latest round: Series A. Backed by OrbiMed. Based in Shanghai, China.
Karl Lintel is a veteran pharma and biotech executive. He is the General Manager of BioShin Limited, the Asia-Pacific commercialization subsidiary of Biohaven Pharmaceuticals. He was appointed to broaden BioShin's senior leadership team with expertise in strategy and business development.
Full founder directory · Investor directory · Company funding database · Fundraising library